Home Cart Sign in  
Chemical Structure| 38647-11-9 Chemical Structure| 38647-11-9

Structure of Triptonide
CAS No.: 38647-11-9

Chemical Structure| 38647-11-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Triptonide, a natural product isolated and purified from the herb of Tripterygium wilfordii Hook.f. with antileukemic, antitumor, anti-inflammatory activities, is effective in the treatment of autoimmune diseases. Triptonide can effectively inhibit canonical Wnt/β-catenin signaling by targeting the downstream C-terminal transcription domain of β-catenin or a nuclear component associated with β-catenin.

Synonyms: PG 492; NSC 165677

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Triptonide

CAS No. :38647-11-9
Formula : C20H22O6
M.W : 358.39
SMILES Code : O=C1OCC2=C1CC[C@@]3(C)[C@@]2([H])C[C@H]4[C@@]5(O4)C([C@]6(C(C)C)[C@@H](O6)[C@H]7[C@]53O7)=O
Synonyms :
PG 492; NSC 165677
MDL No. :MFCD00210566
InChI Key :SWOVVKGLGOOUKI-ZHGGVEMFSA-N
Pubchem ID :65411

Safety of Triptonide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 cells 1, 5, 10, 20 ng/ml 1, 6, 12, 18 hours To investigate the effect of Triptonide on IL-37 mRNA expression. Results showed that 20 ng/ml of Triptonide upregulated IL-37 mRNA expression approximately 3.2-fold after 12 hours of incubation. Cell Mol Immunol. 2015 Jul;12(4):515-8
Rat intestine 3–9 μg/mL 10 minutes Evaluate the absorption characteristics of Triptonide in rat intestine, showing that its absorption extent and rate were independent of concentration. Chin Med. 2018 Jan 8;13:1
THP-1 cells 20 ng/ml 16 hours To investigate the effect of Triptonide on IL-37 protein expression. Results showed that 20 ng/ml of Triptonide upregulated IL-37 protein expression approximately 3.4-fold after 16 hours of incubation. Cell Mol Immunol. 2015 Jul;12(4):515-8
ARPE-19 cells 10-100 nM 24 hours To evaluate the effect of Triptonide on cell viability, results showed no significant impact on cell viability at concentrations below 100 nM. Int J Mol Med. 2024 Sep;54(3):76
Müller cells (MIO-M1) 10-100 nM 24 hours To evaluate the effect of Triptonide on cell viability, results showed no significant impact on cell viability at concentrations below 100 nM. Int J Mol Med. 2024 Sep;54(3):76
Human retinal capillary endothelial cells (HRCECs) 10-100 nM 24 hours To evaluate the effect of Triptonide on cell viability, results showed no significant impact on cell viability at concentrations below 100 nM. Int J Mol Med. 2024 Sep;54(3):76
Human umbilical vein endothelial cells (HUVECs) 10-100 nM 24 hours To evaluate the effect of Triptonide on cell viability, results showed no significant impact on cell viability at concentrations below 100 nM. Int J Mol Med. 2024 Sep;54(3):76
RKO cells 5 nM 24 hours Did not block BIO-induced β-catenin nuclear translocation Sci Rep. 2016 Sep 6;6:32779
HEK293 cells 5 nM 24 hours Did not affect Wnt3a-CM-induced β-catenin levels Sci Rep. 2016 Sep 6;6:32779
SKBR3 0.2 µM 24, 48, 72 hours Inhibits cell growth Sci Rep. 2021 Jan 28;11(1):2408
MCF7 0.2 µM 24, 48, 72 hours Inhibits cell growth Sci Rep. 2021 Jan 28;11(1):2408
MDA-MB-231 0.2 µM 24, 48, 72 hours Inhibits TNBC cell growth Sci Rep. 2021 Jan 28;11(1):2408
BT549 0.2 µM 24, 48, 72 hours Inhibits TNBC cell growth Sci Rep. 2021 Jan 28;11(1):2408
HCC1806 0.2 µM 24, 48, 72 hours Inhibits TNBC cell growth and induces apoptosis Sci Rep. 2021 Jan 28;11(1):2408
U-2OS cells 5, 10, 25, 50, 100, 250 and 1000 nM 48 hours TN inhibited the proliferation of U-2OS cells in a dose-dependent manner with an IC50 of 97.2 nM Cancer Manag Res. 2020 Jul 17;12:5919-5929
MG63 cells 5, 10, 25, 50, 100, 250 and 1000 nM 48 hours TN inhibited the proliferation of MG63 cells in a dose-dependent manner with an IC50 of 108.6 nM Cancer Manag Res. 2020 Jul 17;12:5919-5929
BT-549 0–320 nM 70 hours Inhibited TNBC cell proliferation with an IC50 of 12.1 nM. Breast Cancer Res. 2021 Dec 18;23(1):116
SW480 cells 16.8 nM (IC50) 72 hours Induced apoptosis Sci Rep. 2016 Sep 6;6:32779
MDA-MB-468 0–320 nM 70 hours Inhibited TNBC cell proliferation with an IC50 of 14.4 nM. Breast Cancer Res. 2021 Dec 18;23(1):116
MDA-MB-231 0–320 nM 70 hours Inhibited TNBC cell proliferation with an IC50 of 15.6 nM. Breast Cancer Res. 2021 Dec 18;23(1):116
Pancreatic cancer cell Panc1 8 nM 72 hours Inhibited the LXR-SREBF1-PNKP signaling pathway, increased DNA strand breaks, and induced apoptosis Cell Death Differ. 2020 Aug;27(8):2433-2450
Pancreatic cancer cell Patu8988 8 nM 72 hours Inhibited the LXR-SREBF1-PNKP signaling pathway, increased DNA strand breaks, and induced apoptosis Cell Death Differ. 2020 Aug;27(8):2433-2450
ST2 cells 10 nM 72 hours Triptonide blocks the Wnt signaling pathway by binding to the C-terminal transactivation domain of β-catenin, thereby inhibiting C91-induced osteoblast differentiation in ST2 cells. Front Endocrinol (Lausanne). 2022 Jul 18;13:926622

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Cynomolgus monkeys Adult male C57BL/6J and CD-1 mice, adult male cynomolgus monkeys Oral 0.1 mg/kg Mice: once daily for 3-4 weeks; Monkeys: once daily for 5-6 weeks To evaluate the efficacy and safety of Triptonide as a male contraceptive. Results showed that Triptonide induced sperm deformation and loss of motility, leading to male infertility within 3-4 weeks (mice) and 5-6 weeks (monkeys), with no discernable systematic toxic side effects. Nat Commun. 2021 Feb 23;12(1):1253
Mice Adult male C57BL/6J and CD-1 mice, adult male cynomolgus monkeys Oral 0.8 mg/kg Mice: once daily for 3-4 weeks; Monkeys: once daily for 5-6 weeks To evaluate the efficacy and safety of Triptonide as a male contraceptive. Results showed that Triptonide induced sperm deformation and loss of motility, leading to male infertility within 3-4 weeks (mice) and 5-6 weeks (monkeys), with no discernable systematic toxic side effects. Nat Commun. 2021 Feb 23;12(1):1253
C57BL/6 male mice Light-induced and N-Methyl-D-aspartic acid (NMDA)-induced retinal injury models Intravitreal injection 2 µl of Tn (1 mg/ml) Single injection, lasting 7 days To evaluate the protective effect of Triptonide on light-induced and NMDA-induced retinal injury, results showed that Triptonide pretreatment significantly improved retinal function and structure and inhibited choroidal neovascularization. Int J Mol Med. 2024 Sep;54(3):76
NOD-SCID female mice TNBC MDA-MB-231 xenograft model Intraperitoneal injection 3 mg/kg Once daily for 95 days Suppressed TNBC tumor growth and lung metastasis with a tumor inhibitory rate of 98%. Breast Cancer Res. 2021 Dec 18;23(1):116
Sprague-Dawley rats Single-pass intestinal perfusion model Intestinal perfusion 3–9 μg/mL Single perfusion, lasting 80 minutes Evaluate the absorption characteristics of Triptonide in rat intestine, showing that its absorption extent and rate were independent of concentration. Chin Med. 2018 Jan 8;13:1
Nude mice MDA-MB-231 xenograft model Oral gavage 5 mg/kg Once daily for 17 days Inhibits xenograft tumor growth Sci Rep. 2021 Jan 28;11(1):2408
Nude mice Pancreatic cancer Patu8988 xenograft model Intraperitoneal injection 5 mg/kg/d Once daily for 73 days Inhibited tumor growth, with complete elimination of tumors in five out of eight xenograft mice and an overall inhibition rate of 99.6% Cell Death Differ. 2020 Aug;27(8):2433-2450

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.79mL

0.56mL

0.28mL

13.95mL

2.79mL

1.40mL

27.90mL

5.58mL

2.79mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories